Market Outlook Snapshot Market Dynamics Regional Forecast Country Insights Segment Analysis Competitive Landscape Industry News report.faq_name
On This Report

AI in Oncology for Analytical Solutions Market Size & Growth Forecast 2026–2035, By Segments (Component, Cancer Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Report ID: FBI 14945| Published Date: Jul-2026| Format: PDF, Excel
MARKET OUTLOOK

Market Size and Growoth Outlook

AI in Oncology for Analytical Solutions Market size was around USD 1.37 Billion in 2025 and is slated to grow at a 34.1% CAGR from 2026 to 2035, exceeding USD 25.76 Billion by 2035. The industry revenue for 2026 is assessed at USD 1.8 billion.

Base Year Value (2025)
USD 1.37 Billion
CAGR (2026-2035)
34.1%
Forecast Year Value (2035)
USD 25.76 Billion
Historical Data Period
2022-2025
Largest Region
North America
Forecast Period
2026-2035

Get more details on this report

Request Free Sample Report
SNAPSHOT

AI in Oncology for Analytical Solutions Market Intelligence Snapshot

Regional Market Dynamics

  • North America held a 60.90% market share in 2025, supported by established oncology infrastructure, widespread digital health adoption, and stronger AI integration across clinical and research workflows.
  • Asia Pacific is projected to grow at a 37.51% CAGR, driven by rising AI-enabled healthcare adoption, increasing oncology investments, and expanding use of data-driven analytical tools across clinical settings.

Segment Momentum

  • Software Solutions accounted for 59.96% of the market in 2025 because they provide the core platforms for oncology data analysis, workflow integration, visualization, and clinical decision support.
  • Bladder Cancer is the fastest-growing segment as healthcare providers increasingly adopt AI-driven analytics to improve case interpretation, monitoring, and data-supported clinical decision-making.

Market Expansion Drivers

  • Rising global cancer incidence driving demand for AI-powered early diagnosis and treatment optimization.
  • Expansion of AI-enabled clinical decision support systems improving oncology workflow efficiency.
  • Increasing integration of multimodal healthcare data improving predictive oncology analytics accuracy.

Leading Market Participants

FORECAST SNAPSHOT

Global Market Forecast Snapshot

Market Outlook

Leading players in the AI in oncology for analytical solutions market include Tempus AI, Inc. (United States), Flatiron Health, Inc. (United States), Oracle Corporation (United States), Medidata Solutions, Inc. (United States), GNS Healthcare, Inc. (United States), Cancer Research Horizons Limited (United Kingdom), PathAI, Inc. (United States), Paige.AI, Inc. (United States), ConcertAI, LLC (United States), SOPHiA GENETICS SA (Switzerland).

Regional and Segment Outlook

North America
MARKET DYNAMICS

Market Growth Drivers and Industry Trends

Rising global cancer incidence driving demand for AI-powered early diagnosis and treatment optimization

As cancer case volumes rise, oncology teams are under greater pressure to identify disease earlier, prioritize high-risk patients, and tailor treatment decisions with limited specialist capacity. This is pushing adoption in the AI in oncology for analytical solutions market toward tools that can process imaging, pathology, genomic, and clinical data faster than conventional review pathways, helping clinicians detect patterns associated with early-stage disease and likely treatment response. Hospitals and cancer centers are increasingly evaluating analytical platforms not only for diagnostic support, but also for their ability to reduce delays in triage and therapy selection, which is reinforcing market demand for solutions that fit directly into real-world oncology decision timelines.

Expansion of AI-enabled clinical decision support systems improving oncology workflow efficiency

The spread of AI-enabled clinical decision support is shaping the AI in oncology for analytical solutions market by making analytical outputs more actionable at the point of care rather than confining them to retrospective review. Oncology practices are adopting these systems to streamline case prioritization, align treatment recommendations with evolving evidence, and reduce the manual burden associated with reviewing large volumes of patient data, pathology results, and imaging findings. This practical workflow value is influencing market adoption because buyers increasingly favor platforms that can shorten review cycles, support multidisciplinary tumor boards, and integrate with existing clinical systems without adding friction to already complex oncology operations.

Increasing integration of multimodal healthcare data improving predictive oncology analytics accuracy

A major shift in the AI in oncology for analytical solutions market is the growing ability to combine data from radiology, pathology, genomics, laboratory records, and electronic health records into unified analytical models. This integration improves the precision of predictive outputs by allowing AI systems to capture clinically relevant relationships that are often missed when data sources are analyzed in isolation, which is supporting market development for platforms built around interoperable data architecture and advanced model training. Providers and research-driven cancer programs are placing greater value on solutions that can translate fragmented oncology data into more reliable risk stratification, treatment response prediction, and patient monitoring insights, aiding market expansion through clearer clinical utility.

Growth Driver Impact on CAGR Regulatory Influence Geographic Relevance Adoption Rate Impact Timeline
Increasing AI-driven oncology analytics adoption 9.80% Short term (≤ 2 yrs) North America, Europe (spillover: Asia Pacific) Medium Fast
Integration with clinical trial & hospital systems 8.10% Medium term (2–5 yrs) Europe, Asia Pacific (spillover: North America) High Moderate
Advances in predictive oncology algorithms 6.40% Long term (5+ yrs) North America, Europe (spillover: Asia Pacific) Medium Slow
Rising global cancer incidence driving demand for AI-powered early diagnosis and treatment optimization 2.40% High North America, Europe High Near Term
Expansion of AI-enabled clinical decision support systems improving oncology workflow efficiency 2.10% High North America, Asia Pacific High Mid Term
Increasing integration of multimodal healthcare data improving predictive oncology analytics accuracy 1.80% High North America, Europe Emerging Long Term
CUSTOM RESEARCH

Unlock insights tailored to your business with our bespoke market research solutions.

Click to get your customized report now.

Request Customization →
REGIONAL FORECAST

Regional Demand Dynamics

Polymer Modified Bitumen Market
Largest Region
North America
60.90% Market Share in 2025
North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the leading position in 2025, accounting for a 60.90% share of the AI in oncology for analytical solutions market. This leadership is underpinned by the region’s established oncology care infrastructure, broad use of digital health systems, and stronger integration of AI tools into clinical and research workflows. In practice, hospitals, cancer centers, and research institutions across the region are better positioned to generate, organize, and analyze large oncology datasets, which supports wider deployment of analytical solutions for diagnosis support, treatment planning, and biomarker-focused research.

Asia Pacific is projected to expand at a 37.51% CAGR over the forecast period in the AI in oncology for analytical solutions market. Growth is being propelled by the increasing adoption of AI-enabled healthcare technologies, rising investment in oncology capabilities, and expanding use of data-driven tools across clinical settings. As healthcare providers in the region continue incorporating digital platforms into cancer care and research activity, demand is accelerating for analytical solutions that can process complex patient and disease data more efficiently within evolving oncology workflows.

Parameter North America Asia Pacific Europe Latin America MEA
Innovation Hub i Scale Nascent Developing Advanced
Cost-Sensitive Region i Scale Low Medium High
Regulatory Environment i Scale Restrictive Neutral Supportive
Demand Drivers i Scale Weak Moderate Strong
Development Stage i Scale Emerging Developing Developed
Adoption Rate i Scale Low Medium High
New Entrants / Startups i Scale Sparse Moderate Dense
Macro Indicators i Scale Weak Stable Strong
COUNTRY INSIGHTS

Key Country Insights

Germany 🇩🇪

Precision Diagnostics Support

Germany focuses on integrating AI analytics into precision oncology workflows to improve diagnostic consistency and treatment planning. German healthcare providers emphasize clinically validated algorithms and interoperability with hospital information systems for practical deployment.

France 🇫🇷

Research Collaboration Network

France encourages collaborative development of AI oncology analytical solutions through research hospitals and academic partnerships. French organizations prioritize secure health data utilization and clinically relevant analytics that support precision medicine initiatives.

Italy 🇮🇹

Hospital Workflow Optimization

Italy is incorporating AI analytical solutions into oncology care to improve diagnostic efficiency and multidisciplinary treatment planning. Italian healthcare providers emphasize practical integration with existing clinical workflows while supporting evidence-based cancer management.

Japan 🇯🇵

Imaging Analytics Advancement

Japan advances AI in oncology analytical solutions by strengthening imaging interpretation and early cancer detection capabilities. Japanese healthcare institutions increasingly combine artificial intelligence with diagnostic imaging platforms to support clinician efficiency and standardized assessments.

South Korea 🇰🇷

Digital Oncology Ecosystem

South Korea is strengthening AI-driven oncology analytics through digital hospitals and advanced health data infrastructure. Local technology developers collaborate with healthcare providers to refine analytical platforms supporting personalized oncology research and clinical decision-making.

United States 🇺🇸

Clinical Data Integration

The U.S. prioritizes AI-powered oncology analytics that integrate genomic, imaging, and clinical datasets to improve treatment decision support. Healthcare organizations in the U.S. continue expanding collaborations between technology developers, research institutions, and cancer centers for validated analytical solutions.

SEGMENT ANALYSIS

Segment Leadership and Growth Trends

AI in Oncology for Analytical Solutions Market Share (%), Component, 2025

Software Solutions
Analytics and Other Services
Data Licensing Services

Go beyond the chart, access full insights & data tables

Request Free Sample Report
Component Segment Analysis: Software Solutions (Largest Segment) vs Data Licensing Services (Fastest-Growing Segment)

Within the AI in oncology for analytical solutions market, Software Solutions held the strongest position in 2025 with a 59.96% share. This leadership is underpinned by the central role software platforms play in turning oncology data into usable analytical outputs for clinical, research, and operational workflows. Buyers in this market typically depend on software as the core layer for model deployment, visualization, workflow integration, and decision support, which keeps demand concentrated in this segment. Its established presence across day-to-day analytical use cases gives Software Solutions a durable advantage in the AI in oncology for analytical solutions market.

Data Licensing Services is the fastest-growing segment in the AI in oncology for analytical solutions market because the performance of oncology-focused AI tools increasingly depends on access to high-quality, structured, and usable datasets. As analytical models become more specialized by cancer indication and use case, organizations need licensed data sources that can support training, validation, and continuous refinement. This is giving Data Licensing Services stronger momentum than more established component categories, as growth is being driven by the rising need for dependable data inputs rather than by platform replacement cycles.

Cancer Type Segment Analysis: Breast Cancer (Largest Segment) vs Bladder Cancer (Fastest-Growing Segment)

Breast Cancer accounted for the largest position in the AI in oncology for analytical solutions market in 2025, representing a 32.65% share. Its leadership reflects the depth of analytical activity surrounding breast cancer, where AI applications can be aided by broader data availability, established screening and diagnostic workflows, and sustained research attention. These conditions make breast cancer a practical priority area for analytical solution deployment, helping it maintain the largest share in the AI in oncology for analytical solutions market.

Bladder Cancer is emerging as the fastest-growing segment in the AI in oncology for analytical solutions market as demand rises for more targeted analytical support in areas where interpretation, monitoring, and case stratification can benefit from AI-driven methods. Growth is gaining pace here because expanding analytical adoption is often stronger in cancer types where there is room to improve data-driven decision processes and workflow efficiency. Compared with more mature oncology applications, bladder cancer is seeing faster momentum as adoption moves into less saturated but increasingly relevant clinical and research settings.

Segment Sub-Segment Largest Segment Fastest Growing
Component Data Licensing Services, Software Solutions, Analytics and Other Services Software Solutions Data Licensing Services
Cancer Type Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Kidney Cancer, Non-Hodgkin Lymphoma, Bladder Cancer Breast Cancer Bladder Cancer
Competitive Landscape

Competitive Landscape and Market Positioning

Key companies in the AI in oncology for analytical solutions market:

1. Tempus AI Inc. (United States)

2. Flatiron Health Inc. (United States)

3. Oracle Corporation (United States)

4. Medidata Solutions Inc. (United States)

5. GNS Healthcare Inc. (United States)

6. Cancer Research Horizons Limited (United Kingdom)

7. PathAI Inc. (United States)

8. Paige.AI Inc. (United States)

9. ConcertAI LLC (United States)

10. SOPHiA GENETICS SA (Switzerland)

The AI in oncology for analytical solutions market is advancing through integration of intelligent diagnostic and predictive modeling systems. Advanced analytics is improving clinical decision support and treatment personalization. The AI in oncology for analytical solutions market is also witnessing growing use of multi-modal data integration for improved accuracy. Innovation is strongly driven by precision medicine requirements.

Company Market Share Company Revenue Revenue CAGR (%) Product Portfolio Geographic Presence Innovation / R&D Focus Strategic Developments
No companies available.
🔒 This section is available as a standalone purchase. Buy only the data you need. Inquire Before Buying
Industry News

Industry Development/News

Company Name Date Key Development
Medtronic plc Aug-22 Medtronic launched the GI Genius intelligent endoscopy module in India, an AI-enabled colonoscopy assistance system designed to enhance colorectal cancer detection. The solution improves lesion visualization during procedures, supporting clinicians with real-time decision assistance and strengthening adoption of AI-based diagnostic augmentation in gastrointestinal oncology workflows across clinical settings.
Cleveland Clinic Sep-21 Cleveland Clinic researchers and Owkin, Inc. announced a deep-learning model designed to predict survival outcomes in hepatocellular carcinoma patients. The model leverages AI-based clinical and biological data integration to improve prognostic accuracy, supporting more personalized oncology decision-making and advancing computational approaches in liver cancer outcome prediction.
PathAI Jan-24 PathAI launched six additional oncology indications for its PathExplore platform, expanding its AI-driven tumor microenvironment analysis capabilities using digitized pathology slides. The expansion enhances standardized characterization of cancer tissues, supporting translational research and enabling broader application of AI-powered pathology tools across multiple cancer types.
ConcertAI Jun-24 ConcertAI collaborated with NVIDIA to strengthen its CARA AI platform for translational and clinical development applications. The integration enhances computational performance and AI model development capabilities, enabling more efficient oncology data analysis and improving scalability of real-world evidence generation for cancer research and drug development workflows.
F. Hoffmann-La Roche Ltd. Sep-24 Roche collaborated with Qritive to accelerate adoption of AI-enabled cancer diagnostics in pathology workflows. The partnership focuses on improving clinical decision support for pathologists through AI-driven analysis tools, aiming to enhance diagnostic accuracy and streamline pathology interpretation processes in oncology care environments.
Insilico Medicine Sep-24 Insilico Medicine partnered with Inimmune to apply its Chemistry42 AI platform for accelerating discovery of next-generation immunotherapeutics. The collaboration integrates AI-driven molecular design with immunology-focused drug development, supporting faster identification of candidate compounds and enhancing R&D efficiency in oncology-related therapeutic innovation.
Visage Imaging GmbH Jan-21 Visage Imaging received regulatory clearance for its Visage Breast Density AI medical device, supporting radiological assessment of breast tissue density. The solution contributes to breast cancer screening workflows by enhancing image-based risk evaluation, reflecting early regulatory adoption of AI-enabled diagnostic support tools in oncology imaging applications.
Report Customization

Explore This Report

Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.

1 report.custom report.segments 2 Custom TOC 3 Related Reports

AI in Oncology for Analytical Solutions Market — Custom Segments

Segment Sub-Segment
No segment data available.

AI in Oncology for Analytical Solutions Market — report.custom

Custom Chapter Custom Details
No custom TOC data available.

Need a different cut of the data?

Request Custom Research
report.faq_name

What is the current size of the AI in oncology for analytical solutions market?

As of 2026 the market size of AI in oncology for analytical solutions is valued at USD 1.8 billion.

What are the growth projections for the AI in oncology for analytical solutions industry?

AI In Oncology For Analytical Solutions Market size is likely to expand from USD 1.37 billion in 2025 to USD 25.76 billion by 2035 posting a CAGR above 34.1% across 2026-2035.

How is the growing reliance on licensed oncology datasets reshaping AI-driven analytical capabilities in oncology workflows?

Increasing dependence on structured, high-quality licensed datasets is enabling more specialized cancer-specific AI models. This is improving training, validation, and continuous refinement, making data access a core procurement driver alongside software adoption in oncology analytics workflows.

Why are multimodal data integration capabilities becoming central to adoption decisions in AI-based oncology analytical platforms?

Integrated use of imaging, pathology, genomics, and clinical records is improving predictive accuracy by capturing cross-data relationships. Buyers increasingly prioritize platforms that unify fragmented datasets to support stronger risk stratification and treatment response insights.

Why do software solutions lead the AI in oncology for analytical solutions market?

Software Solutions accounted for 59.96% of the market in 2025 because they provide the core platforms for oncology data analysis, workflow integration, visualization, and clinical decision support.

Which cancer type segment is growing the fastest in the AI in oncology for analytical solutions market?

Bladder Cancer is the fastest-growing segment as healthcare providers increasingly adopt AI-driven analytics to improve case interpretation, monitoring, and data-supported clinical decision-making.

Why does North America lead the AI in oncology for analytical solutions market?

North America held a 60.90% market share in 2025, supported by established oncology infrastructure, widespread digital health adoption, and stronger AI integration across clinical and research workflows.

Why is Asia Pacific the fastest-growing region for AI in oncology analytical solutions?

Asia Pacific is projected to grow at a 37.51% CAGR, driven by rising AI-enabled healthcare adoption, increasing oncology investments, and expanding use of data-driven analytical tools across clinical settings.

Who are the leading players in the AI in oncology for analytical solutions landscape?

Leading players in the AI in oncology for analytical solutions market include Tempus AI, Inc. (United States), Flatiron Health, Inc. (United States), Oracle Corporation (United States), Medidata Solutions, Inc. (United States), GNS Healthcare, Inc. (United States), Cancer Research Horizons Limited (United Kingdom), PathAI, Inc. (United States), Paige.AI, Inc. (United States), ConcertAI, LLC (United States), SOPHiA GENETICS SA (Switzerland).
Testimonials

Our Clients

"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."

Quality Assurance Manager

"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."

R&D Manager

"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."

Senior Marketing Manager
THE RESEARCH BEHIND THIS REPORT

Our Research Team & Methodology

Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.

THIS REPORT'S RESEARCH VERTICAL

Research Team Overview

♢
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.

Prepared by the Healthcare & Medical Devices Research Team

10+
Industry Verticals
100+
Countries Analyzed
5–7
Days Standard
Delivery
12k+
Research Reports
Published
On-
Demand
Customized Research
Available
6
Months Analyst
Support
PDF + XLS
Report Deliverables

Trust & Compliance

☷D&B D-U-N-S
♢GDPR & CCPA Compliant
♙ISO 9001 Certified (ISO 9001:2015)
♙SSL Encryption
▭Secure Payments
✓Confidential Handling

Research Domains

10 coverage areas
Medical Devices & Equipment Diagnostic Imaging Clinical Diagnostics Digital Health & Telemedicine Patient Monitoring Systems Surgical & Minimally Invasive Technologies Healthcare IT & Data Systems Biotechnology & Life Sciences Pharmaceutical Technologies Healthcare Delivery & Services

Research Intelligence

Executive Leadership
Product & Technology Experts
Manufacturing & Operations Leaders
Procurement & Supply Chain Professionals
Sales & Commercial Executives
Channel Partners & Distribution Networks
Enterprise Buyers & End Users
Industry Consultants & Regulatory Experts

Research Workflow & Quality Assurance

📥
01

Data Collection

Verified information gathered through primary and secondary research.

🔍
02

Data Triangulation

Cross-validation using multiple independent data sources.

📈
03

Forecast Modelling

Market estimates developed using historical trends and analytical models.

👨‍💼
04

Analyst Validation

Findings reviewed by domain experts for accuracy and consistency.

📝
05

Editorial & Quality Review

Final editorial, quality, and compliance checks before publication.

✅
06

Final Publication

Released after successful completion of the internal review process.

Report Coverage

📊 Market Assessment

  • Market Size & Forecast
  • Market Segmentation
  • Regional Analysis
  • Growth Drivers & Challenges
  • Market Dynamics

🏢 Competitive Intelligence

  • Competitive Landscape
  • Company Profiles
  • Competitive Benchmarking
  • Mergers & Acquisitions
  • Market Share Analysis or Key Company Strategies

🔍 Strategic Analysis

  • Value Chain Analysis
  • Porter's Five Forces
  • PESTLE Analysis
  • Pricing Trends
  • Supply-Demand Analysis

🚀 Future Outlook

  • Technology Landscape
  • Regulatory Landscape
  • Investment & Funding Landscape
  • Emerging Opportunities
  • Future Market Outlook

Have a question about this report or need a custom scope?

Request Customization
License

Select License Type

Single User
US$ 4,250
Buy Now
Corporate User
US$ 6,150
Buy Now

Want this data scoped to your exact question?

Tell us the segments, regions, or competitors you need answered — an analyst will confirm scope before any custom work starts.

Talk to an Analyst →